Friday, December 22, 2017

Ignyta To Be Acquired By Roche For $1.7 Billion

San Diego-based precision medicine developer Ignyta has agreed to be acquired by biopharmaceuticals giant Roche, in a $1.7 billion deal, the two said late Thursday evening. According to the two, they are in a definitive merger agreement, where Roche will acquire Ignyta for $27.00 per share in cash, or $1.7 billion. The companies said the price is a premium of 74% on Ignyta's closing price on Thursday.

---